Our vision… is to be the global leaders in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.

GW is developing a portfolio of cannabinoid medicines, of which the lead product is Sativex, an oromucosal spray for the treatment of MS symptoms, cancer pain and neuropathic pain.